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UbcH5 is the key ubiquitin-conjugating enzyme
catalyzing ubiquitination during TNF-a-triggered
NF-kBactivation. Here, we identified an herb-derived
sesquiterpene lactone compound IJ-5 as a preferen-
tial inhibitor of UbcH5 and explored its therapeutic
value in inflammatory and autoimmune disease
models. IJ-5 suppresses TNF-a-induced NF-kB
activation and inflammatory gene transcription by in-
hibiting the ubiquitination of receptor-interacting
protein 1 and NF-kB essential modifier, which is
essential to IkB kinase activation. Mechanistic inves-
tigations revealed that IJ-5 preferentially binds to and
inactivates UbcH5 by forming a covalent adduct with
its active site cysteine and thereby preventing ubiq-
uitin conjugation to UbcH5. In preclinical models,
pretreatment of IJ-5 exhibited potent anti-inflamma-
tory activity against TNF-a- and D-galactosamine-
induced hepatitis and collagen-induced arthritis.
These findings highlight the potential of UbcH5 as a
therapeutic target for anti-TNF-a interventions and
provide an interesting lead compound for the devel-
opment of new anti-inflammation agents.
INTRODUCTION
Tumor necrosis factor alpha (TNF-a) is a central regulator of
inflammation, and its proinflammatory activity is crucially medi-
ated by the transcription factor NF-kB (Chen and Goeddel,
2002). While TNF-a and NF-kB are required for protective inflam-
matory responses, excessive production of TNF-a and resulting
aberrant activation of NF-kB are attributed to pathologies of
several autoimmune and inflammatory diseases. Therefore, tar-
geted modulation of the TNF-a/NF-kB pathway is an attractive
therapeutic approach for treatment of inflammatory diseases.
TNF-a initiates the NF-kB pathway by triggering the recruit-
ment of the TNF receptor signaling complex (TNF-RSC) consist-Chemistry & Biology 21, 1341–1ing of TNF receptor-associated death domain protein (TRADD),
TNF receptor-associated factor 2 (TRAF2), the cellular inhibitor
of apoptosis proteins 1 and 2 (c-IAP1 and c-IAP2), and recep-
tor-interacting protein 1 (RIP1) (Chen and Goeddel, 2002). The
formation of TNF-RSC leads to the recruitment and activation
of the transforming growth factor b-activated kinase 1 (TAK1)
complex and the IkB kinase (IKK) complex. The IKK complex
has two catalytic subunits, IKK-a and IKK-b, and a regulatory
subunit, NF-kB essential modifier (NEMO). Once activated, IKK
phosphorylates the NF-kB inhibitor IkB and targets it for protea-
somal degradation. Subsequently, NF-kB is liberated to enter
the nucleus to turn on downstream genes involved in immune
and inflammatory responses. TAK1 is believed to be an up-
stream kinase that phosphorylates and activates IKK. In addi-
tion, other kinases such as MAP3K3 and MAP3K8 have been
suggested to be recruited to TNF-RSC and mediate IKK activa-
tion (Karin and Gallagher, 2009). It was also proposed that
upstream kinases may not be necessary for IKK activation and
IKK might be activated by trans-autophosphorylation (Ha¨cker
and Karin, 2006).
Recent studies establish a prominent role of ubiquitination in
the activation of IKK. Ubiquitination is a hierarchical enzymatic
cascade in which a ubiquitin (Ub)-activating enzyme (E1)
activates Ub and transfers it to the active site cysteine of a Ub-
conjugating enzyme (E2), then the resulted E2-Ub conjugate co-
operates with a Ub ligase (E3) to transfer Ub to the lysine residue
of target proteins (Pickart and Eddins, 2004). Once Ub is conju-
gated to the target proteins, other Ub molecules can be conju-
gated to one of the seven lysines (K6, K11, K27, K29, K33,
K48, K63) on the preexisting Ub, forming polyubiquitin (polyUb)
chains of different linkages. Ub molecules can also be linked
through their N- and C-terminals in a head-to-tail-like fashion
to form linear chains. PolyUb chains of different linkages serve
distinct functions: K48-linked polyUb chains target proteins for
proteasomal degradation, while K63-linked chains function in
signal transduction (Bianchi and Meier, 2009). The human
genome encodes two E1s, 50 E2s, and over 700 E3s. In the
case of TNF-a signaling, c-IAPs are demonstrated to function
as the key E3s to attach polyUb chains to RIP1 (Bertrand et al.,
2008; Varfolomeev et al., 2008). Polyubiquitinated RIP1 binds
to NEMO, thereby recruiting the IKK complex to TNF-RSC to350, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1341
Figure 1. Chemical Structure of IJ-5
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et al., 2006). The c-IAP-generated polyUb chains also function as
scaffolds to recruit the linear ubiquitin assembly complex
(LUBAC), the E3 ligase that further assembles linear polyUb
chains on NEMO and other substrates in TNF-RSC (Gerlach
et al., 2011; Haas et al., 2009). Recent data suggest that
LUBAC-catalyzed linear polyUb chains may be particularly
important for TNF-a-induced NF-kB activation (Kensche et al.,
2012; Rahighi et al., 2009; Tokunaga et al., 2009). It has been
proposed that linear polyUb chains conjugated on NEMO are
recognized by another NEMO molecule, thereby inducing the
multimerization of the IKK complex and the trans-autophosphor-
ylation of IKK. Alternatively, they might function as a scaffold to
recruit other upstream kinase(s) to phosphorylate and activate
IKK (Iwai and Tokunaga, 2009).
Several E2 enzymes are possibly involved in TNF-a signaling,
as LUBAC can use multiple E2s, including UbcH5, E2-25, and
UbcH7, to generate linear polyUb chains (Kirisako et al., 2006),
and c-IAPs can act in partnership with UbcH5 and Ubc13-
Uev1A to catalyze K63 or K11 ubiquitination of RIP1 (Bertrand
et al., 2008; Dynek et al., 2010). UbcH5 is an E2 enzyme family
consisting of three homologs—UbcH5a, UbcH5b, and UbcH5c
(Jensen et al., 1995). UbcH5 was originally found as an E2 family
that can support IKK activation in crude cell extracts (Chen et al.,
1996). Recently, UbcH5s are further identified as critical partners
of c-IAPs to specifically mediate ubiquitination of RIP1 in TNF-a
signaling (Dynek et al., 2010; Varfolomeev et al., 2008; Xu et al.,
2009). UbcH5 can also cooperate with LUBAC to generate a
linear polyUb chain on NEMO (Kirisako et al., 2006; Tokunaga
et al., 2009). Furthermore, RNAi-mediated UbcH5 knockdown
significantly inhibits TNF-a-induced RIP1 ubiquitination, IKK
activation (Xu et al., 2009), and NF-kB-regulated gene transcrip-
tion (Dynek et al., 2010). Therefore, UbcH5may serve as a poten-
tial target for modulation of TNF-a activity.
Inula japonica Thunb is an herb that has long been used in
Traditional Chinese Medicine for the treatment of inflammatory
diseases such as bronchitis, arthritis, hepatitis, etc. (Choi
et al., 2010; Park et al., 2011). Our recent efforts to elucidate
its mechanisms of action suggested that a class of com-
pounds, sesquiterpene lactones (SLs), were active constitu-
ents (Qin et al., 2010). By screening SL compounds derived
from this herb, we herein discovered a compound 1b-hydrox-
yalantolactone (Figure 1), termed as IJ-5 since it was isolated
from I. japonica Thunb, which can inhibit TNF-a-induced
NF-kB activation. Further mechanistic investigations led to1342 Chemistry & Biology 21, 1341–1350, October 23, 2014 ª2014 Ethe identification of UbcH5 as the molecular target for IJ-5.
Moreover, pretreatment of IJ-5 exhibited potent in vivo anti-in-
flammatory activities in both TNF-a- and D-galactosamine (D-
GalN)-induced acute hepatitis and collagen-induced arthritis
(CIA) rodent models. This study shows that UbcH5 is a drug-
gable target for anti-inflammatory therapy and small-molecule
inhibition of UbcH5 represents a promising approach for the
development of therapeutics targeting the TNF-a/NF-kB
pathway.
RESULTS
IJ-5 Suppresses TNF-a/NF-kB Pathway
With a limited screen of I. japonica Thunb-derived SLs for their
inhibitory activities on TNF-a-induced NF-kB reporter expres-
sion in 293T cells, we identified IJ-5 as a potent inhibitor showing
a dose- and time-dependent inhibitory effect (Figure 2A).
Immunoblotting assay revealed that IJ-5 (2.5–10 mM) dose-
dependently suppressed TNF-a-induced IKK-b and IkBa phos-
phorylation and prevented IkBa degradation in 293T cells, while
showing no effect on TNF-a-induced c-Jun N-terminal kinase
(JNK) phosphorylation and only a slight inhibition on p38 phos-
phorylation at 10 mM (Figure 2B). In nonstimulated cells, IJ-5
treatment alone did not alter the protein levels and the phosphor-
ylation status of IKK-b and IkBa (Figure 2C). These results indi-
cate that IJ-5 selectively blocks the TNF-a-activated NF-kB
pathway by suppressing IKK activation. Furthermore, IJ-5 is
less effective in inhibiting IL-1b-induced NF-kB activation, as it
showed only a modest inhibitory effect on IL-1b-induced KKb
and IkBa phosphorylation and IkBa degradation at 10 mM, and
no inhibitory effect could be observed at 2.5 and 5 mM (Fig-
ure 2D), the concentrations at which IJ-5 already showed
remarkable inhibitory activities on TNF-a-induced NF-kB activa-
tion (Figure 2B). The above results indicate that IJ-5 preferen-
tially interfere with the TNF-a-activated NF-kB pathway. IJ-5
(2.5–10 mM) also dose-dependently suppressed TNF-a-induced
expressions of NF-kB-targeted inflammatory genes, including
MCP-1, ICAM, and VCAM-1, in Bend.3 mouse endothelial cells,
as well as expressions of IL-6, IL-8, and MCP-1 in human syno-
vial fibroblasts (Figure 2E). Immunoblotting assay revealed that
TNF-a-induced IKK-b and IkBa phosphorylation and IkBa
degradation in these cells were all suppressed by IJ-5 within
the same dose range (Figure S1A available online). MTT assay
showed that IJ-5 is not cytotoxic to these cells within this dose
range (Figure S1B), excluding the possibility that the observed
inhibition on NF-kB activation and gene expressions by IJ-5
arise from cytotoxicity.
UbcH5 Is Identified as a Molecular Target for IJ-5
The suppression of IKK activation by IJ-5 might come from its
direct inhibition on IKK or other upstream kinase(s). However,
IJ-5 showed no direct inhibitory effects on all of the protein
kinases that may mediate IKK-b phosphorylation, including
IKK-b, IKK-a, IKKε, TAK1, MAP3K14, MAP3K3, MAP3K8,
PI3K, PKBa, PKBb, PKCq, PKCz, PKCε, and TBK1, when as-
sayed at 30 mM in vitro using Millipore’s KinaseProfiler and Invi-
trogen’s Z’-LYTE screening platform (Tables S1 and S2), and no
interactions between IJ-5 and these kinases were detectable at
DiscoveRx’s KINOMEscan screening platform (Table S3),lsevier Ltd All rights reserved
Figure 2. IJ-5 Inhibits TNF-a-Induced NF-kBPathway Activation and
Inflammatory Gene Expression
(A) 293T cells cotransfected with NF-kB firefly luciferase plasmid and
TK-Renilla plasmidwere treatedwith IJ-5 (2.5–10 mM) for 4 hr (left), or with 5 mM
IJ-5 for various lengths of time (0.5–8 hr) (right), and stimulated with 10 ng/ml
TNF-a for 6 hr; then the cells were lysed and the relative NF-kB luciferase
activity was measured.
(B) 293T cells were treated with IJ-5 for 4 hr and stimulated with 10 ng/ml
TNF-a for 15 min, and then the levels of IKK-b, IkBa, p38, and JNK and their
phosphorylated levels were detected by immunoblotting.
(C) 293T cells were treated with IJ-5 alone for 4 hr or stimulated with 10 ng/ml
TNF-a for 15 min, and then the levels of IKK-b and IkBa and their phosphor-
ylated levels were detected by immunoblotting.
(D) 293T cells were treated with IJ-5 for 4 hr and stimulated with 20 ng/ml IL-1b
for 15 min, and then the levels of IKK-b and IkBa and their phosphorylated
levels were detected by immunoblotting.
The results in (B), (C), and (D) are representative of three experiments.
(E) bEnd.3 mouse endothelial cells and human synovial fibroblasts were
treated with IJ-5 for 4 hr and stimulated with 10 ng/ml TNF-a for 6 hr, and then
the mRNA levels of indicated genes were detected by real-time quantitative
RT-PCR (qRT-PCR).
The results in (A) and (E) are means ± SEM obtained from three independent
experiments. The statistic difference is indicated as *p < 0.05. See also Fig-
ure S1 and Tables S1–S3.
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Instead, IJ-5 (2.5–10 mM) dose-dependently suppressed TNF-
a-stimulated ubiquitination of RIP1 and NEMO in 293T cells (Fig-
ure 3A), suggesting IJ-5 may target one or more components of
the ubiquitin system and thereby impeding the synthesis of pol-
yUb chains essential to IKK activation. To narrow down the
potential target(s) for IJ-5, we tested its activity against the for-
mation of polyUb chains in in vitro ubiquitination systems, in
which recombinant c-IAP1 or HOIP/RNF31, the core com-
ponents of the LUBAC complex, was used as the E3 enzyme, re-Chemistry & Biology 21, 1341–1combinant UbcH5c, E2-25K, or UbcH7 was used as the E2
enzyme, and recombinant UBE1 was used as the E1 enzyme.
IJ-5 exhibited an inhibitory effect on the polyUb chain formation
catalyzed by c-IAP1 and UbcH5c (Figure 3B). IJ-5 also inhibited
the linear chain formation catalyzed by HOIP/RNF31 and
UbcH5c (Figure 3C). Interestingly, when UbcH5c was
substituted with other E2s (UbcH7 and E2-25K) in the above sys-
tem, IJ-5 showed no inhibitory effects anymore (Figure 3D).
Because the E3 enzyme (HOIP/RNF31), E1 enzyme, and Ub
were common to all three in vitro reactions tested, we excluded
these components as targets of IJ-5. The remaining possible
target for IJ-5 was thus the E2 enzyme UbcH5c.
To further delineate the IJ-5mechanismof action, we tested its
activity on the loading of Ub to different E2s in in vitro Ub-loading
assays. The results demonstrated that IJ-5 (2.5–10 mM) dose-
dependently inhibited Ub loading to UbcH5c (Figure 3E). IJ-5
also inhibited Ub loading to the other two members of the
UbcH5 family, UbcH5a and UbcH5b, with similar inhibitory po-
tency, but exhibited an obviously weaker inhibitory effect against
Ub loading to Ubc13. Furthermore, IJ-5 did not affect the Ub
loading to UbcH7, E2-25K, UbcH6, and UbcH10 (Figure 3E).
When assayed at 10 mM, IJ-5 also showed no inhibitory effects
on Ub loading to other E2 enzymes, including Ube2B, UbcH6,
UbcH8, UbcH9, Ubc7, Ube2J2, Ubc1, UbcH2, CDC34,
CDC34B, Ube2S, Ube2T, and Ube2W (Figure S2). These data
suggested IJ-5 is an E2 enzyme inhibitor that is selective for
the UbcH5 family.
We next detected the direct interactions between IJ-5 and
different E2s using surface plasmon resonance (SPR). The re-
sults showed that IJ-5 bound to UbcH5a, UbcH5b, UbcH5c,
and Ubc13 immobilized on the sensor chips (Figure 4A). Further
determination of its binding affinity to isoforms of UbcH5 the
family demonstrated a small window of selectivity among
UbcH5a, UbcH5b, and UbcH5c with apparent dissociation con-
stants (KD) of 5.189 mM, 3.578 mM, and 2.577 mM, respectively.
Consistent with its weak inhibitory activity against Ubc13, IJ-5
bound to Ubc13 with a relatively low affinity, as the KD of IJ-5
binding to Ubc13 was measured at 13.37 mM. Furthermore, no
interacting resonance signal was detected when up to 62.5 mM
IJ-5 flowed over the sensor chip coated UbcH6, UbcH7,
UbcH10, or E2-25K (data not shown), indicating that IJ-5 does
not bind to these E2s.
To test whether IJ-5 can target UbcH5 in cells, we performed
pull-down experiments using IJ-5-conjugated sepharose beads.
Both endogenous UbcH5 in human synovial fibroblast lysates
and recombinant UbcH5c were pulled down by IJ-5-conjugated
sepharose beads, but not by IJ-5-free control beads. Existence
of free IJ-5 resulted in obvious decline in the amounts of
captured UbcH5 by IJ-5-conjugated bead (Figure 4B), indicating
that free IJ-5 can compete with conjugated IJ-5 in binding to
UbcH5, suggesting the binding is saturable and specific. Further
examination of IJ-5’s effect on the Ub loading to endogenous
UbcH5 in cells demonstrated that IJ-5 inhibited the Ub loading
to endogenous UbcH5 in human synovial fibroblasts in a
dose- and time-dependent manner (Figure S3), suggesting
that the compound also inactivates UbcH5 in cells. Together,
these data clearly confirm that IJ-5 directly binds to and in-
activates UbcH5 in cells, thus indicating that UbcH5 is a target
for IJ-5.350, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1343
Figure 3. IJ-5 Inhibits Formation of PolyUb Chains and Selectively Prevents Ub Loading to UbcH5
(A) IJ-5 inhibits TNF-a-induced ubiquitination of RIP1 and NEMO in 293T cells. 293T cells were treated with IJ-5 at indicated concentrations for 4 hr, followed by
stimulation with 10 ng/ml TNF-a for 5min. Cell lysates were immunoprecipitated (IP) with anti-RIP1 or anti-NEMO antibodies and analyzed by immunoblotting (IB)
with anti-Ub.
(B) IJ-5 inhibits polyUb chain synthesis catalyzed by c-IAP1 and UbcH5c in vitro. The in vitro ubiquitination reaction containing purified c-IAP1, UbcH5c, UBE1,
and Ub was carried out in the presence of IJ-5. The reaction products were analyzed by immunoblotting with an anti-Ub antibody.
(C) IJ-5 inhibits linear polyUb chain synthesis catalyzed by LUBAC and UbcH5c in vitro. The assay was carried out as in (B), except that HOIP/RNF31, instead of
c-IAP1, was used as the E3. The reaction products were analyzed by immunoblotting with an anti-Ub antibody.
(D) IJ-5 exhibits no inhibitory effect on E2-25K- or UbcH7-mediated linear polyUb chain synthesis. The assay was carried out as in (C), except that E2-25K or
UbcH7, instead of UbcH5c, was used as the E2.
The results in (A)–(D) are representative of three independent experiments.
(E) IJ-5 selectively prevents Ub loading to UbcH5. E1 were incubated for 45 min with different E2s and Ub in the presence of IJ-5, and the ubiquitin-loading
reactions were then started by the addition of ATP. Reactions were terminated by denaturation in SDS-PAGE sample buffer without a reducing agent (DTT);
proteins were subjected to SDS-PAGE in the absence of any thiol unless specified and analyzed by immunoblotting with anti-E2 antibodies.
See also Figure S2.
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Catalytic Cysteine Residue
As an SL compound, IJ-5 contains an a,b-unsaturated carbonyl
moiety, which is known to bind covalently to free cysteine thiol
groups of proteins by Michael addition (Merfort, 2011; Zhang
et al., 2005). UbcH5 contains two free cysteine residues at posi-
tions 85 and 111 (Jensen et al., 1995). TheCys85 is the E2 active-
site residue that accepts activated Ub from E1. Based on the
finding that IJ-5 can bind to UbcH5 and inhibit Ub loading to
it, we predicted that IJ-5 might be able to form a covalent adduct
with Cys85 via Michael addition and thereby inactivating UbcH5.
To test this prediction, we incubated recombinant UbcH5c with
or without IJ-5 and digested the proteins with trypsin and
analyzed using online liquid chromatography (LC)-Orbitrap colli-
sion-induced dissociation (CID) tandem mass spectrometry
(MS/MS). The incubation with IJ-5 led to a defined mass change
of one peptide with molecular masses of 1145.62 derived from
the digestion of UbcH5c protein that was directly measured by
high-resolution MS with high confidence (Figure S4A). This pep-
tide fragment contains UbcH5c’s active site cysteine, Cys85.
The mass shift suggests that UbcH5c was modified by IJ-5 at
Cys85 (Figure S4B). CID fragmentation MS/MS was also used
to localize themodification site with single amino acid resolution.
Detection of precursor ions at high resolution and a nearly com-
plete series of fragmentation ions from CID allowed the accurate
sequencing and assignment of the modification site to Cys85
(Figures S4C and S4D). Interestingly, no mass shift was found
on the peptide with molecular mass of 1353.73, which contain1344 Chemistry & Biology 21, 1341–1350, October 23, 2014 ª2014 Eanother free cysteine, Cys111, suggesting that the covalent
binding is sterically selective for Cys85.
Based on the above results, the terminal carbon atom of
a-methylene moiety of IJ-5 and the sulfur atom of Cys85 were
specified as the ligand reactive group and the receptor bond.
To investigate the binding mode of IJ-5 and UbcH5c, we further
performed the covalent docking simulation using Maestro soft-
ware (Schro¨dinger, version 9.0). From the proposed binding
mode, it can be found that the stereo conformation of IJ-5 can
fit well with the binding site around reactive cysteine residue
Cys85, and the hydroxyl and carbonyl groups of IJ-5 can form
additional hydrogen bonds with the amino groups of Gln92 and
Asn114 of UbcH5c, respectively (Figure 5).
IJ-5 Exerts Anti-inflammatory Effects In Vivo
To evaluate the therapeutic value of IJ-5 for treatment of inflam-
matory diseases, we tested its in vivo anti-inflammatory effects in
the TNF-a- and D-GalN-induced hepatitis model and CIA model.
In the hepatitis model, all of the TNF-a- and D-GalN-chal-
lenged mice died within 12 hr, whereas only 30% of the IJ-5-
treated mice died within 96 hr (n = 20), with 14 of 20 animals
being long-term survivors (8 weeks) (Figure 6A). IJ-5 treatment
also protectedmice from TNF-a- andD-GalN-induced liver dam-
age as shown by a significant inhibition of liver enzyme release
(Figure 6B). Moreover, the livers of TNF-a- and D-GalN-chal-
lenged mice showed marked inflammatory cell infiltration and
hepatocyte damage in liver sections, which were remarkably
ameliorated in IJ-5-treated mice (Figure 6C). The protectivelsevier Ltd All rights reserved
Figure 4. The Direct Interactions between
IJ-5 and E2 Enzymes
(A) Kinetics of IJ-5 binding to UbcH5s and Ubc13
determined by SPR. The purified UbcH5a, UbcH5b,
UbcH5c, or Ubc13 was covalently immobilized
onto the CM5 sensor chip. IJ-5 (3.9 mM blue line,
and then in ascending order, 7.8, 15.625, 31.25,
and 62.5 mM lines) was injected over at a flow rate of
30 ml/min. The surface was regenerated between
injections with 5 mMNaOH. The kinetic parameters
of Ka, Kd, and KD were measured with BIAcore
evaluation software using a 1:1 binding model.
(B) The binding of IJ-5 to Ubch5 detected by
pull-down. Synovial fibroblast lysates (left) or re-
combinant UbcH5c (right) was incubated with IJ-5-
coupled sepharose beads or control beads in the
absence or presence of free IJ-5, and the bead-
captured proteins were subjected to SDS-PAGE
and immunoblotting with an anti-UbcH5 antibody.
See also Figures S3 and S4.
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mRNA expressions of IL-6, MCP-1, ICAM-1, and VCAM-1 (Fig-
ure 6D). These data confirmed that IJ-5 can protect the mice
from TNF-a-induced hepatic failure.
In the CIA model, daily intraperitoneal injection of IJ-5 (2–
10 mg/kg per day) beginning on day 21 postimmunization
dose-dependently decreased the severity of CIA in comparison
with vehicle-treated arthritic mice, as assessed by the clinical
score (Figure 7A). Radiological examination showed that the
bone erosion was also prevented by IJ-5 treatment (Figures 7B
and S5A). Histopathological analyses of joints revealed that IJ-
5-treatedmice have significantly reduced synovitis andmononu-
clear cell infiltration (Figures 7C and S5B). Analysis of the hind
paw joints showed that treatment with IJ-5 dose-dependently in-
hibited CIA-induced mRNA expression of the proinflammatory
factors, including TNF-a, IL-1b, IL-6, MCP-1, MMP3, and
MMP13 (Figure 7D). Accordingly, the serum levels of several cy-
tokines, including TNF-a, IL-1b, and IL-6, in the arthritic mice
were also decreased by IJ-5 treatment in a dose-dependent
manner (Figure 7E). These results indicate that IJ-5 treatment re-
duces the arthritic inflammatory response by downregulating
expression of proinflammatory factors in inflamed joints. Impor-
tantly, no deaths or any other obvious adverse effects were de-
tected in the IJ-5-treated mice during the study, indicating that
IJ-5 is safe in mice at its effective anti-inflammatory dose. We
had also treated mice with IJ-5 alone (intraperitoneally [i.p.]
10 mg/kg once daily for 21 days) and dissected all mice after
treatment to detect its toxicity to normal tissues. No detectable
abnormalities were observed in the organs examined, including
liver, kidney, spleen, heart, lung, and pancreas (data not shown),
further indicating the safety of IJ-5.Chemistry & Biology 21, 1341–1350, October 23, 2014DISCUSSION
Given the critical role of ubiquitination in
the regulation of TNF-a-stimulated NF-kB
activation, the ubiquitin system should be
amenable to therapeutic intervention of
the disorders associated with uncontrolledTNF-a production and aberrant NF-kB activation (Iwai, 2012).
Obviously, c-IAPs and LUBAC, the E3 ligases specifically
involved in the TNF-a/NF-kB pathway, represent the most
attractive targets due to their intrinsic specificity for particular
protein substrates. However, the lack of catalytic pockets for
small-molecule binding and high reliance on protein-protein in-
teractions to mediate their activity has made small-molecule
targeting toward these E3 ligases challenging (Eldridge and
O’Brien, 2010). Actually, no small molecule has been found to
directly inhibit their E3 ligase activity. E1 perform the first com-
mon step of Ub activation in ubiquitination. The enzymaticmech-
anism of E1s suggests that they are more ‘‘druggable.’’ To date,
several small-molecule E1 inhibitors have been identified and
used asmeans to probe the biology of ubiquitin system (Eldridge
and O’Brien, 2010). A recently identified E1 inhibitor PYR41 has
been found to inhibit the ubiquitination of upstream signaling
molecules, thereby attenuating cytokine-mediated NF-kB acti-
vation. Thus, the potential of using an E1 inhibitor therapeutically
in inflammatory processes has been proposed (Yang et al.,
2007). However, since there are only two E1s in human, E1-
directed strategies could impact a wide variety of ubiquitin path-
ways, thereby eliciting unexpected toxicity. Compared to E1
enzymes, E2s are more numerous (50 in human genome).
Each E2 enzyme often functions with a single or limited number
of E3 ligases to transfer E1-activated Ub to substrate proteins,
and thus selective E2 inhibitors will provide specificity unattain-
able with E1 inhibitors. Several E2 enzymes, including UbcH5,
Ubc13, E2-25, and UbcH7, have been suggested to be involved
in the NF-kB pathway (Bianchi and Meier, 2009; Dynek et al.,
2010; Kirisako et al., 2006). Inhibition of one or more of
these E2s may suppress NF-kB activation and inflammatoryª2014 Elsevier Ltd All rights reserved 1345
Figure 5. The Proposed Binding Mode of IJ-5 and UbcH5c
UbcH5c (Protein Data Bank ID code 1X23) is shown as the surface (pale green)
and IJ-5 (yellow), and the key residues (cyan) are represented as sticks.
Hydrogen bonds were identified according to rational bond angles and dis-
tances, which are indicated by red dashed lines. Oxygen, nitrogen, and sulfur
atoms are shown in red, blue, and yellow, respectively.
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and LUBAC to synthesize polyUb chains of different linkages,
including K63, K11, and linear chains (Dynek et al., 2010; Kiri-
sako et al., 2006; Tokunaga et al., 2009; Varfolomeev et al.,
2008; Xu et al., 2009). In the past few years, growing evidence
has revealed that these polyUb chains catalyzed by UbcH5
play a pivotal role in TNF-a-mediated NF-kB activation (Bianchi
and Meier, 2009; Dynek et al., 2010; Iwai and Tokunaga, 2009;
Kensche et al., 2012; Kirisako et al., 2006; Rahighi et al., 2009;
Tokunaga et al., 2009; Xu et al., 2009). More interestingly,
RNAi-mediated knockdown of UbcH5 inhibits IKK activation by
TNF-a but not IL-1b, whereas knockdown of Ubc13 blocks IKK
activation by IL-1b but not TNF-a, suggesting different stimuli
may employ distinct E2 enzymes to regulate NF-kB activation
(Xu et al., 2009). In this regard, UbcH5may serve as a viable ther-
apeutic target for anti-TNF-a interventions. Recently, small-
molecule E2 inhibitors were also discovered, but none of them
are highly selective for UbcH5. For example, the NF-kB inhibitor
BAY-11-7082was recently found to exert its effects via inactivat-
ing Ubc13 and UbcH7 by forming a covalent adduct with their
reactive cysteine residues (Strickson et al., 2013). Nevertheless,
BAY-11-7082 inactivates almost all E2s and is therefore a broad-
spectrum E2 inhibitor. Another compound, NSC697923, was
initially identified as a selective inhibitor of Ubc13-Uev1A and in-
hibited NF-kB activation in diffuse large B cell lymphoma cells
(Pulvino et al., 2012). However, it was found afterward to inacti-
vate a number of other E2 enzymes including UbcH5c (Strickson
et al., 2013). Therefore, this compound is also not a selective E2
inhibitor. Due to the lack of selective inhibitors of UbcH5, the
potential of the UbcH5-targeting therapeutic strategy have not
been evaluated in a preclinical setting.
In the present study, we discovered a natural compound, IJ-5,
which inhibits the TNF-a/NF-kB pathway by inactivating UbcH5.
It is noteworthy that IJ-5 is an SL compound isolated from
I. japonica Thunb, an herb with anti-inflammatory properties
(Choi et al., 2010; Park et al., 2011). SLs actually comprise a large
group of secondary plant metabolites mostly found in the Aster-1346 Chemistry & Biology 21, 1341–1350, October 23, 2014 ª2014 Eaceae family (Merfort, 2011; Zhang et al., 2005), and plant ex-
tracts rich in SLs are frequently used in traditional medicine for
the treatment of inflammatory diseases (Heinrich et al., 1998).
In recent years, the anti-inflammatory properties of SLs have at-
tracted a great deal of interest, and several plant-derived SLs
were found to exert potent anti-inflammatory activity via selec-
tive inhibition of the NF-kB pathway (Bork et al., 1997; Lyss
et al., 1997). Further mechanistic investigations revealed that
these SLs act either by directly inhibiting the catalytic activity
of IKK-b or by targeting the p65 subunit of NF-kB and preventing
its DNA-binding activity (Kim et al., 2007; Kwok et al., 2001; Lyss
et al., 1998). The present finding that IJ-5 inhibits NF-kB activa-
tion by targeting UbcH5 provides an additional possible molec-
ular basis for the anti-inflammatory properties of SLs and further
supports the notion that various SLs inactivate different steps
along the NF-kB pathway by acting on distinct protein targets.
All SLs contain a common functional structure, a a,b-unsatu-
rated carbonyl moiety, which can react with nucleophiles, espe-
cially the cysteine thiol groups by Michael-type addition, thus
forming stable adducts (Merfort, 2011; Zhang et al., 2005).
Such reaction can lead to the disruption of various cysteine-
dependent structural proteins and enzymes. This means that
the thiol-reactivity of SLs is an underlying mechanism respon-
sible for their bioactivities. IKK-b contains a critical cysteine res-
idue (Cys179) in its catalytic domain, and some SLs, including
parthenolide and artemisolide, have been demonstrated to inac-
tivate IKK-b by covalent modification of Cys179 (Kim et al., 2007;
Kwok et al., 2001). The NF-kB subunit p65 bears a critical
cysteine residue (Cys38) in its DNA-binding domain, and an SL
compound helenalin has been shown to selectively alkylate
Cys38 of p65, thereby preventing its DNA-binding activity
(Lyss et al., 1998). E2 enzymes also bear a cysteine residue at
the active site, which is critical to E2’s catalytic activity because
it accepts activated Ub from E1 (Pickart and Eddins, 2004). Here
we provide evidence that the inactivation of UbcH5 by IJ-5 is
dependent on its thiol reactivity. Our MS/MS analysis clearly
demonstrated that IJ-5 covalently modifies the active site
cysteine (Cys85) of UbcH5c. Molecular docking of IJ-5 against
UbcH5c further indicated that the formed covalent bond be-
tween the terminal carbon atom of a-methylene moiety of IJ-5
and the sulfur atom of Cys85 in UbcH5c is favorable for the bind-
ing. The location of this modification site is consistent with the
ability of IJ-5 to inhibit Ub loading to UbcH5c.
Notably, the thiol-reactivity of IJ-5 is selective toward Cys85 of
UbcH5. First, IJ-5 neither interacts with IKK-b nor directly inhibit
its catalytic activity, indicating that, unlike other SLs, this SL
compound cannot modify Cys179 of IKK-b. Second, by com-
parative analysis of its effects on Ub loading to different E2
enzymes, we demonstrated that IJ-5 only exhibits obvious inhib-
itory effects against UbcH5s and Ubc13 among themore than 20
different E2s tested and UbcH5s are more sensitive than Ubc13
to the inhibition by IJ-5. Third, in SPR analysis of direct interac-
tions between IJ-5 and several E2s, only the bindings of IJ-5 to
UbcH5s and Ubc13 were detectable, and IJ-5 bound to UbcH5s
with higher affinity than to Ubc13. Finally, UbcH5c bears two free
cysteine residues (Cys85 and Cys111), but only Cys85 is cova-
lently modified by IJ-5, indicating the thiol reactivity of IJ-5 is ste-
rically selective for Cys85 of UbcH5. In the proposed binding
mode of IJ-5-UbcH5c, IJ-5 binds to the Cys85-located pocketlsevier Ltd All rights reserved
Figure 6. IJ-5 Protects Mice against TNF-a-
and D-GalN-Induced Hepatitis
BALB/c mice were administered i.p. with either IJ-5
(10 mg/kg) or the same volume of vehicle. One hour
later, hepatitis was induced by one intraperitoneal in-
jection of TNF-a (15 mg/kg) and D-GalN (700 mg/kg).
(A) Survival rates of the mice were monitored over a
period of 72 hr (n = 10).
(B) Serum ALT levels measured at 3, 6, and 9 hr after
TNF-a and D-GalN challenge.
(C) Representative sections prepared from liver tis-
sues collected at 6 hr after TNF-a and D-GalN chal-
lenge and stained with hematoxylin-eosin (3200).
Arrows indicate the damaged hepatocytes and in-
filtrated inflammatory cells.
(D) The hepaticmRNA levels of IL-6,MCP-1,MCP-2,
ICAM-1, and VACM-1 determined at 6 hr after TNF-a
and D-GalN administration using qRT-PCR.
The results in (C) and (D) represent mean ± SEM of
ten mice per group. The results are representative of
three independent experiments. The statistic differ-
ence is indicated as *p < 0.05.
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covalent link between IJ-5’s alkylating reactive moiety and
UbcH5c’s Cys85, two hydrogen bonds were observed between
IJ-5 and residues around Cys85 (Figure 5). Such noncovalent
interactions might serve as an initial site-recognition step when
IJ-5 binds to UbcH5 and hence raise the probability of the cova-
lent reaction and stabilize the covalent adduct between IJ-5 and
Cys85 of UbcH5. Based on above analysis, we assume that the
molecular geometry of IJ-5 and the chemical environment
around the target thiol group might be the factors that possibly
determined the reactive selectivity of IJ-5 toward Cys85 of
UbcH5. A better understanding of the molecular basis for the
selectivity of IJ-5 can be achieved by a IJ-5:E2 cocrystal struc-
tural study in the future.
Even though the exact molecular basis still remains unclear,
the present characterization of IJ-5 demonstrates that UbcH5
is preferentially susceptible to inhibition by this compound at
the catalytic site. This discovery allows us to further evaluate
the therapeutic potential of small-molecule modulation of
UbcH5 for inflammatory diseases. Our in vitro data indicated
that pharmacological inactivation of UbcH5 by IJ-5 led to the in-
hibition of NF-kB activation and inflammatory gene expressions
in TNF-a-stimulated endothelial cells and synovial fibroblasts. In
the preclinical model, pretreatment with 10mg/kg IJ-5 protected
mice against TNF-a- and D-GalN-induced acute hepatitis. This
protection was associated with a significant decrease in TNF-
induced inflammatory cell infiltration as well as inflammatory
gene expression in livers, supporting that IJ-5 exerts its pro-
tective effect by inhibiting the TNF-a-mediated inflammatory
responses in the experimental animals. IJ-5 treatment also
reduced the clinical and pathological manifestations of arthritis
in CIA mice, a prototype animal model for human rheumatoid
arthritis in which TNF-a play an important pathogenic role. Its
anti-inflammatory properties were manifested by marked
improvement in the histology of the inflamed joints and also by
significant reduction of expressions of inflammatory genes in
IJ-5-treated CIA animals. The above data support the notion
that its UbcH5-inactivating activity might confer IJ-5 the abilityChemistry & Biology 21, 1341–1to block NF-kB activation induced by TNF-a and to inhibit its
proinflammatory activities in vivo. Thus, IJ-5 represents the basis
for a potential new class of therapeutics for anti-TNF-a interven-
tions. Nevertheless, considering many other enzymes, such as
deubiquitylases, other cysteine proteinases, and protein tyrosine
phosphatases, also possess the active site cysteine, which
render them susceptible to inactivation by covalent modification
(Krishnan et al., 2013; Love et al., 2007; Powers et al., 2002), and
considering their susceptibilities to inactivation by IJ-5 have not
been tested, we cannot exclude the possibility that the concom-
itant inhibition of these enzymes might also contribute to the
in vivo effects of this compound.
SIGNIFICANCE
Protein ubiquitination has been demonstrated to play a crit-
ical role in the activation of the NF-kB pathway, which is
pivotal to inflammation and immunity (Iwai, 2012). Therefore,
the development and discovery of pharmacological in-
terventions within the ubiquitin system have an enormous
potential for possible novel treatments of inflammatory
and autoimmune disorders. UbcH5 was recently identified
as the key ubiquitin-conjugating enzymemediating the ubiq-
uitination of several important signaling proteins upstream-
ing the activation of IKK in the NF-kB pathways (Dynek et al.,
2010; Tokunaga et al., 2009; Varfolomeev et al., 2008), and
gene knockdown studies have demonstrated that this
enzyme is specially required for IKK activation by proinflam-
matory cytokine TNF-a (Xu et al., 2009), implying UbcH5may
serve as a viable therapeutic target for anti-TNF-a inter-
ventions. Here, we report an herb-derived sesquiterpene
lactone compound IJ-5 that preferentially inactivates
UbcH5 by covalent modification of its active site cysteine.
Accordingly, IJ-5 inhibits TNF-a-stimulated ubiquitination
of two important signaling proteins, receptor-interacting
protein 1 and NF-kB essential modifier, thereby suppressing
TNF-a-triggered IKK and NF-kB activation and inflammatory
gene expressions in in vitro cultured cells. In the TNF-a- and350, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1347
Figure 7. IJ-5 Ameliorates CIA in Mice
Arthritis was induced in mice by twice immuniza-
tion with type II collagen on day 0 and day 21. IJ-5
was administered i.p. at 2 mg/kg and 10 mg/kg
daily between day 24 and day 35 postim-
munization.
(A) The severity of CIA in control and IJ-5-treated
mice evaluated every 2 days by two independent
observers under blinded conditions (n = 10).
(B) Representative radiographs of the knee joints
of mice in different groups on day 37. Bone erosion
sites are indicated with arrows.
(C) Representative knee joint sections stained with
hematoxylin-eosin (3200) on day 37. Arrows show
severe synovial inflammation.
(D) The mRNA levels of different inflammatory
genes in the hind paw joints of CIA mice assessed
by real-time PCR on day 37.
(E) Serum levels of different proinflammatory cy-
tokines assayed by ELISA on day 37.
The results in (D) and (E) are mean ± SEM of ten
mice per group. The results are representative of
three independent experiments. The statistic dif-
ference is indicated as *p < 0.05. See also Fig-
ure S5.
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10 mg/kg IJ-5 exerted preventive anti-inflammatory effects.
Moreover, IJ-5 also exhibited therapeutic activity in the
collagen-induced arthritis mouse model at 2 and 10 mg/kg
doses. The above characterization of IJ-5 demonstrates
that UbcH5 is susceptible to inhibition by this compound at
its catalytic site and pharmacologically inactivating UbcH5
may offer an effective treatment for TNF-a-based inflamma-
tory diseases. Bases on these findings, we emphasize the
potential of UbcH5 as a therapeutic target for TNF-a-medi-
ated disorders and provide an interesting lead compound
for the generation of new anti-inflammatory agents.
EXPERIMENTAL PROCEDURES
Reagents
IJ-5 was isolated from the aerial part of I. japonica Thunb in our laboratory by
using methods as previously described (Qin et al., 2010). Recombinant human
TNF-a and IL-1b were purchased from Peprotech.
Cells
293T cells and bEnd.3 mouse endothelial cells were purchased from ATCC
and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) sup-
plemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (GIBCO).
Synovial fibroblasts were isolated from synovium obtained from rheumatoid
arthritis patients who had undergone total joint replacement surgery or syno-
vectomy as previously described (Zimmermann et al., 2001). The study was
approved by the Second Military Medical University Institutional Review1348 Chemistry & Biology 21, 1341–1350, October 23, 2014 ª2014 Elsevier Ltd All rights resBoard. Cells were used at passage 5 or older, at
which time they were a homogeneous population
of fibroblasts. Synovial fibroblasts were grown in
DMEM supplemented with 10% FBS.
Mice
BALB/c mice (female, 6–8 weeks old) and DBA/1
mice (male, 6–7 weeks old) were purchased from
Shanghai SLAC Laboratory Animal (Shanghai,China). All animal experiments were performed in accordance with Institutional
Animal Research Committee guidelines.
NF-kB Reporter Assay
NF-kB reporter assay was conducted as described in the Supplemental
Experimental Procedures.
Immunoblotting
Immunoblotting assay was conducted as described in the Supplemental
Experimental Procedures.
Real-Time Quantitative PCR
Real-time quantitative PCR was conducted as described in the Supplemental
Experimental Procedures.
Cell Viability Assay
The effect of IJ-5 (2.5–10 mM) on the viability of cells was studied using the
MTT [3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide]-based
cell viability assay according to the instructions of the manufacturer
(Sigma).
Kinase Profiling
IJ-5 was assayed at 30 mM against a penal of recombinant kinases as
described in the Supplemental Experimental Procedures.
Detection for Ubiquitination of RIP1 and NEMO in Cells
293T cells were treated with IJ-5 (0–10 mM) for 4 hr, followed by stimulation
with 10 ng/ml TNF-a for 5 min. The cell were lysed in immunoprecipitation
buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 1 mM EDTA protease
inhibitor cocktail) plus 1% SDS and boiled for 5 min at 95C. Supernatantserved
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were precleared with protein A/G-Sepharose (Santa Cruz Biotechnology)
at 4C for 1 hr. The precleared cell lysates were then mixed with mouse
anti-RIP1 or anti-NEMO antibody (Santa Cruz) and incubated at 4C
for 8 hr. Immunocomplexes were recovered by incubating protein A/G-Se-
pharose for 4 hr, and the resin was washed five times with lysis buffer.
Samples were subjected to SDS-PAGE, followed by immunoblotting
with rabbit anti-Ub, anti-RIP1, or anti-NEMO antibodies (Cell Signaling
Technology).
In Vitro Ubiquitination Assay
In vitro autoubiquitylation assay was performed as described previously
(Pulvino et al., 2012). Recombinant human c-IAP1 or HOIP/RNF31, the core
components of the LUBAC complex, was used as the E3 enzyme, recombi-
nant human UbcH5c, E2-25K, or UbcH7 was used as the E2 enzyme, and re-
combinant UBE1 was used as the E1 enzyme. The recombinant proteins were
all purchased from Boston Biochem. The reactions were carried out in a 25 ml
reaction volume with 100 mM Ub, 0.2 mM E1, 0.5 mM E2, and 0.2 mM E3 in a
buffer containing 25 mM Tris-HCl (pH 7.5), 5 mM MgCl2, and 2 mM ATP.
IJ-5 was added into the reaction mixtures at the indicated concentrations.
Reactions were incubated at 37C for 3 hr, stopped by adding an equal volume
of SDS-PAGE sample buffer, boiled at 95C for 5 min, and immunoblotted with
anti-Ub antibody (Santa Cruz).
E2 Ubiquitin-Loading Assays
The loading of Ub to E2 enzymewas assayed by detecting the formation of E2-
Ub thioester conjugates in a reaction system as described in the Supplemental
Experimental Procedures.
SPR Analysis
SPR analysis was conducted as described in the Supplemental Experimental
Procedures.
Pull-Down Assays
The direct interaction between IJ-5 and UbcH5c was assayed by pull-down
experiment with IJ-5-coupled beads as described in the Supplemental Exper-
imental Procedures.
Determination of IJ-5 Binding Site on UbcH5c
The binding site of IJ-5 on UbcH5c was determined using LC-MS/MS analysis
performed as described in the Supplemental Experimental Procedures.
Covalent Molecular Docking
Molecular docking of IJ-5 on UbcH5c was performed as described in the Sup-
plemental Experimental Procedures.
Evaluation of IJ-5 in TNF-a- and D-GalN-Induced Hepatitis Model
TNF-a- and D-GalN-induced hepatitis studies were performed as described in
the Supplemental Experimental Procedures.
CIA Model
DBA/1 mice were used for the induction of arthritis. CIA studies are described
in detail in the Supplemental Experimental Procedures.
Statistical Analysis
Kaplan-Meier survival analysis (SPSS 10.0; SPSS) was used to compare the
survival probabilities of different groups. All quantitative values are given as
means ± SEM. An unpaired Student’s t test was used to evaluate the differ-
ence between two different treatments, and p < 0.05 was considered to be
statistically significant. Statistical analyses were performed using PRISM
software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
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